semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertriglyceridemia Men and women, ages >18 Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL Provide written informed consent and authorization for protected health information disclosure  Women who are pregnant or lactating, or planning to become pregnant Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects History of pancreatitis History of bariatric surgery or currently on weight loss drugs Uncontrolled hypertension (BP > 160/100) HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin Consumption of more than 2 alcoholic beverages per day History of cancers (except if been disease free for >5 years OR history was basal or squamous cell skin cancer) Participation in another clinical trial involving an investigational agent in the last 30 days Other parameters will be assessed at the study center to ensure for this study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes Mellitus, Type 1 Type 1 diabetes mellitus (T1DM) for at least 1 year and using insulin glargine for at least 6 months with a maximum daily dose of 1 unit per kilogram (U/kg) Hemoglobin A1c (HbA1c) of no greater than 10.5% before randomization Body mass index (BMI) 19 to 45 kilogram per square meter (kg/m²) Capable and willing to prepare and inject insulin with a syringe, monitor own blood glucose, complete the study diary, be receptive to diabetes education, comply with study requirements, and receive telephone calls during treatment Women of childbearing potential must test negative for pregnancy before receiving treatment and agree to use reliable birth control until completing the follow-up  Twice daily use of insulin glargine within 30 days prior to the study Use of any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 3 months prior to the study Use of an insulin pump More than 1 episode of severe hypoglycemia within 3 months prior to the study, or currently diagnosed as having hypoglycemia unawareness or more emergency room visits or hospitalizations due to poor glucose control in the 6 months preceding the study Known hypersensitivity or allergy to any of the study insulins or their excipients Blood transfusion or severe blood loss within 3 months prior to the study or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology Irregular sleep/wake cycle Pregnant or intend to become pregnant during the study Women who are breastfeeding
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Type 2 Diabetes Mellitus Cardiovascular Abnormalities Diabetic patients aged 35 years or older and did not use insulin during the first 5 years of treatment after being diagnosed (with or without symptoms listed in the following criteria) Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl) Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs) Obesity (BMI ≥ 25)  Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the item 1-4) Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease Current diagnosis of end stage renal function with serum creatinine > 2.0 mg/dl or on renal dialysis Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Decompensated Heart Failure patients with New York Heart Association (NYHA) functional class IV heart failure according to the American Heart Association (AHA) classification, namely dyspnea on minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea signs of congestion (third heart sound or pulmonary rales on physical examination) pulmonary congestion on chest x-ray serum B-type natriuretic peptide levels > 400 pg/ml or NT-proBNP > 1500 pg/ml echocardiographic documentation of systolic or diastolic dysfunction age >18 years old on medical therapy with an ACE-inhibitor and/or a β-blocker experiencing an acute decompensation of known chronic HF baseline oxygen saturation <90% on admission arterial blood gas  acute de novo HF severe renal failure (serum creatinine >200 μmol/L or GFR <30 ml/min/1.73m2) admission systolic blood pressure <90 mm Hg severe valvular disease known adverse reactions to furosemide or dopamine HF secondary to congenital heart disease a scheduled procedure with a need for IV contrast dye a scheduled cardiac surgery within 6 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Heart Failure, Congestive Subjects with heart failure and at the age of 18 (inclusive) to 80 (exclusive) Subjects with NYHA Class II-IV with dyspnea Subjects with left ventricular ejection fraction (LVEF) of 40 percent or below on the echocardiogram Eligible subjects who meet the are capable of participating in the study, and provide written informed consent to study participation after receiving a clear explanation about the study objective and nature  A subject who cannot understand or does not agree to the study contents Subjects with conduction defect of 2nd degree or above atrioventricular block Subjects with heart rate less than (<) 60 beats at rest Subjects with systolic blood pressure < 100 mm Hg at rest Subjects with renal failure (serum creatinine > 2.0 milligram per deciliter [mg/dL]) Subjects with unrecovered pulmonary edema Subjects with history of myocardial infarction or stroke within 3 months Subjects with history of coronary intervention or coronary bypass within 6 months Subjects with heart failure due to mitral valve without valve replacement or aortic valvular disease (excluding moderate or less severe mitral insufficiency secondary to left ventricular expansion) Subjects with history of valve replacement within the past 6 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Type 1 Diabetes The subject is between 12 and 18 years of age (inclusive) The subject has had type 1 diabetes, as defined by WHO for at least 1 year or is confirmed C-peptide negative The subject will have been on insulin pump for at least 3 months, with good knowledge of insulin self-adjustment HbA1c ≤ 12% based on analysis from central laboratory  Non-type 1 diabetes mellitus including those secondary to chronic disease Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and MAO inhibitors Known or suspected allergy against insulin Subjects with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the clinician Total daily insulin dose >= 2 IU/kg Postmenarchal girls who are pregnant or intending to become pregnant or are breastfeeding Any coexisting cardiac and respiratory condition (including asthma)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertrophic Cardiomyopathy years Hypertrophic Cardiomyopathy Aortic valve replacement  Atrial fibrillation Pericarditis postoperative low output Preoperative permanent pacemaker placement
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Greater than or equal to 18 years of age NYHA Class III Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months Residual well-demarcated region of LV systolic dysfunction defined as at least 3 consecutive segments of abnormal wall motion by echocardiography read at the echocardiography core laboratory LVEF less than or equal to 40% measured by echocardiography read at the echocardiography core laboratory No left ventricular wall thickness less than 0.5 cm measured by echocardiography read at the echocardiography core laboratory Mitral regurgitation of 0-2+ (inclusive) measured by echocardiography read at the echocardiography core laboratory Subject has an implanted, functional AICD Subject receiving stable optimal pharmacological therapy defined as ACE inhibitor and/or ARB, and Beta-blocker for 90 days with stable dose for 30 days unless contraindicate  Planned revascularization within 30 days following enrollment Estimated Glomerular Filtration Rate < 30 ml/min* Inability to undergo SPECT imaging History of aortic valve regurgitation > 2 Moderate/Severe aortic stenosis defined as AVA <1.5 cm2 Presence of an artificial aortic valve Subjects with aortic aneurysm >3.8 cm History of cancer with exception of basal cell carcinoma and following results on age appropriate cancer screenings Subjects with persistent atrial fibrillation (per ACC/AHA/ESC guidelines, defined as recurrent AF episodes lasting longer than 7 days) Subjects with Biventricular pacing device implant within the last 3 months OR previously implanted Biventricular pacing device with programming planned to be reoptimized following enrollment in this trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Type 2 Diabetes Mellitus Diagnosis of type 2 diabetes mellitus > 5 years HbA1c ≤ 9% Overweight or obese (BMI ≥ 25 kg/m2 and ≤ 30 kg/m2) Age ≥ 30 and ≤ 70 years (postmenopausal if female) Stable medical therapy for past 3 months Stable serum glucose for past 3 months (128-180 mg/Dl) Age between 30 to 50 Use of metformin TG < 240 mg/Dl No alcohol, no insulin, no smoke  Personal history of coronary heart disease Cerebrovascular disease or vascular disease Renal or hepatic disease Inflammatory diseases and thyroid diseases within the last years Use of drugs known to affect glycemic control, beta blockers, any change in daily activity profile, and diet
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Endothelial Dysfunction Newly diagnosed type 2 diabetes Age: 40 >= age <=70 year old  Type 1 diabetes Mitochondrial diabetes Patients with clinical detectable angiopathy Body Mass Index (BMI) > 30 Kg/m2 Age < 40, or > 70 years old Malignant neoplasms, renal or liver diseases Smokers Known diabetes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Type 1 Diabetes Mellitus clinical diagnosis of type 1 diabetes within last 6 months Age 20-45 years fasting basal C-peptide equal or greater than 0.22 nmol/L, lower than 0.8 nmol/L BMI between 17 and 30 at screening  Significant disease or condition other than type 1 diabetes Diabetes-related complications Ongoing treatment with immunosuppressive or immunomodulating agents including chronic corticosteroids
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Diabetic Nephropathy Obesity Women and Men Individuals of any race (recruitment will focus on American Indians and Mexican Americans) years and older  Pregnant Women Children under 18 years old
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 1 Diabetes Insulin Pump Therapy Subject with Type 1 diabetes (>1yr since diagnosis) 2. Medtronic( MiniMed Paradigm 522, 512 , 722 or 712) insulin infusion pump CSII therapy for at least 3 months 3. Age ≥ 18 years 4. HbA1c at ≥ 6.0% 5. No concomitant diseases that influence metabolic control 6. No current use of CGM 7. Subjects do not participate in any other interventional study  Known or suspected allergy to trial products. 2. Any significant diseases or conditions including psychiatric disorders and substance abuse that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study, or compromise patient safety 3. Subject is currently using CGM device 4. Diabetic ketoacidosis in the past 3 months. 5. Severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrollment. 6. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study. 7. Subject is participating in another drug or device study that could affect glucose measurements or glucose management. 8. Female subject who is pregnant or planning to become pregnant within the planned study duration
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Diabetes Mellitus, Type 1 Type I diabetes, durability >5 years Age 20-65 years Normal weight (BMI 19-26 kg/m2) Diabetic treatment with mealtime and bedtime insulin HbA1c ≤10 % Informed consent to participate in the study  Diabetic complications; neuropathy, foot ulcers and/or gastroparesis A known food intolerance of gluten, leguminous plants, nuts or almonds Pregnancy or breast-feeding Concurrent participation in another research study with metabolic effects Previously regular follow-up with a dietician at SDC during the last year Adjustment during the study of medical treatment other than insulin and/or nutritional supplement with metabolic effects Non acceptance of the study diet or food products that are recommended in the study Disability to read and understand the Danish language Unable to receive and/or store the test products Place of residence >1 hr drive from SDC